-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 15, CDE's official website showed that Betta Pharmaceuticals' PD-L1 small molecule inhibitor BPI-371153 was approved for clinical use and is intended for the treatment of patients with locally advanced or metastatic solid tumors or relapsed/refractory lymphoma
Preclinical studies have shown that high-dose BPI-371153 has stronger in vivo anti-tumor activity than PD-L1 monoclonal antibody, and significantly reduces tumor volume
Betta Pharmaceuticals submitted a listing application to the Hong Kong Stock Exchange on February 9, 2021, passed the Hong Kong Stock Exchange hearing on May 30, and submitted a prospectus to the Hong Kong Stock Exchange again on December 2.
Betta Pharmaceutical Pipeline
From: Hong Kong stock prospectus in December
According to the Insight database, there are currently 5 oral PD-L1 small molecule drugs under development in China
In addition, Fosun Pharma has also developed FH-2001, a dual-target PD-L1/FGFR inhibitor, which has not yet been registered to initiate clinical trials
Domestic PD-L1 small molecule drugs entering the clinic
From: Insight database (http://db.
Original title: Betta Pharmaceuticals’ PD-L1 small molecule inhibitor approved for clinical use
